The pharmaceutical industry’s approach to data integrity has been historically manual, leveraging physical documentation and potentially unreliable paper-based ...

AI’s true power lies in pattern recognition across messy, real-world data: Natural language processing extracts phenotypes, comorbidities, and device usability feedback from unstructured clinical ...

Life sciences industry has regulatory compliance at the center of all its operations, so maintaining the integrity of data has always been a pressing need for this industry globally. Regulators such ...

Data content management will drive the growing global data and analytics market in the pharmaceutical sector, which will reach a valuation of $2.1bn by 2028, according to a report. The 2024 edition of ...

Join Dell Technologies for an engaging webinar and Q&A session on Driving Better Business Outcomes with a Data-Centric Approach in Pharma. During this session, we will delve into the world of ...

DUBLIN--(BUSINESS WIRE)--The "Efficient Batch Record Design and Review" training has been added to ResearchAndMarkets.com's offering. This online training is designed for professionals in the ...

Pharma’s finally catching up: real-time data is helping teams move faster, stay compliant and deliver better care where it counts. In the rapidly evolving pharmaceutical and healthcare landscape, ...

In an industry where speed and precision can directly affect patient outcomes, pharma companies are under pressure to ...

Doron Aspitz is the CEO of Verix, a leading provider of AI commercial operations enhancement platforms for the pharmaceutical industry. As the poet once said, “Two paths diverged in a yellow wood,” ...

When it comes to bringing life-saving therapeutics to market, the first significant investment for pharmaceutical companies is within research and development, which includes drug discovery, drug ...

Pharma marketing is shifting from a product-centered approach to one driven by data and engagement, according to Kamya Elawadhi, chief client officer at Doceree. In an interview with Fierce Pharma ...

aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise ...